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Editorial
It is with great pleasure and enthusiasm that we take the
opportunity to introduce the new open access, peer-
reviewed journal Experimental & Translational Stroke Medi-
cine published by BioMed Central. As its title suggests, the
journal is intended principally to gather and disseminate
new knowledge in the field of experimental stroke in
order to facilitate future translation and development of
new clinical stroke treatments. There are many examples
in modern medicine of translational research opening
new perspectives for the improved diagnosis or treatment
of human diseases and enabling findings from basic
bench top discoveries to be transferred into clinical appli-
cations. A good example for this approach in the field of
cerebrovascular disease is diffusion weighted magnetic
resonance imaging. Introduced in the last decade of the
20th century in experimental stroke studies, this novel
diagnostic tool was rapidly and successfully translated to
humans, revolutionized early diagnosis of stroke and rep-
resents now the gold standard of modern stroke imaging
worldwide. Contrary to this success in stroke diagnosis,
the translation of novel experimental therapies into an
effective treatment for stroke patients has so far not been
successful for a number of reasons, with one central prob-
lem certainly rooted in insufficient stringency of the trans-
lational process from bench to bedside. A clear goal of the
journal is therefore to improve the quality of experimental
stroke research and reduce translational failures from
bench to bedside.
The new journal particularly focuses on translational
aspects of pathophysiological, diagnostic and therapeutic
issues of cerebrovascular diseases. We encourage authors
to submit full-length original articles, short reports or
reviews related to the topics of emerging therapies, diag-
nostics, models, animal behaviour testing, pathophysiol-
ogy, and clinical trial data. Moreover, guest articles
summarizing translational aspects of other neurological
diseases apart from stroke may occasionally be featured.
Following evaluation by the Editorial Board [1] and peer-
review by two independent experts in the field, all
accepted articles will be published online immediately
and soon after listed in PubMed. We believe that the open
access model featured by BioMed Central is ideally suited
to rapidly and broadly disseminating novel findings, and
promoting fruitful discussion among active stroke
researchers, with the ultimate goal of providing recom-
mendations and guidelines aimed at improving experi-
mental and translational stroke research.
Fittingly, the launch articles provide detailed reviews on
promising stroke drug candidates which are currently in
late clinical development, such as the hematopoietic fac-
tors G-CSF [2] and EPO [3]. Gee and colleagues address
long term immunologic consequences of experimental
stroke and mucosal tolerance. They provide clear-cut evi-
dence that although induction of immunological toler-
ance to MBP improves outcome after stroke, mucosal
administration of antigen could also account for detri-
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mental autoimmunity in the long run [4]. The guest article
by R. Linker provides an in depth review on multiple scle-
rosis models away from the old experimental autoim-
mune encephalitis (EAE) concept towards the clinically
more relevant conditional knockout models tailored to
study the pathology of B cells, CD 8 cells, and inflamma-
tion as a pathological trigger for primary degeneration [5].
We strongly believe that the open access format of the new
journal - a true novelty in the field of cerebrovascular
research - has clear benefits for science, medicine and the
general public: First, all articles are freely and universally
accessible online, and so an author's work can be read by
anyone at no cost. The easy and widespread availability of
articles significantly enhances reading and citation of the
results. Second, all accepted articles are immediately pub-
lished with no delay and therefore allow particularly rapid
dissemination of new results. Third, the BioMed Central
format allows interactive discussion and anotation of arti-
cles providing an online tool for open discussion of data.
Fourth, in contrast to other stroke journals, there is no size
restriction for articles, and the type of data that can be
attached to an article (movies, large image data etc.).
Authors hold copyright for their work and grant anyone
the right to reproduce and disseminate the article, pro-
vided that it is correctly cited. Finally, the journal's articles
are archived in PubMed Central, the US National Library
of Medicine's full-text repository of life science literature,
and also in repositories at the University of Potsdam in
Germany, at INIST in France and in e-Depot, the National
Library of the Netherlands' digital archive of all electronic
publications. This complies with the policies of a number
of funding bodies including the Wellcome Trust, NIH and
Howard Hughes Medical Institute.
We hope that unlimited access to the latest information
on stroke research published in Experimental & Transla-
tional Stroke Medicine will create new ideas and opportuni-
ties to improve the understanding of stroke and to find
new treatment opportunities. We encourage the stroke
research community to make full use of this very welcome
resource.
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